Other Events. On June 26, 2026, Soligenix, Inc. (the “Company”) filed a prospectus supplement (the “Current Prospectus Supplement”) to increase the maximum aggregate offering amount of the shares of the Company’s common stock, par value $0.001 per share, issuable under the At Market Issuance Sales Agreement, dated January 23, 2026 (the “Sales Agreement”), with Rodman & Renshaw LLC, by an additional aggregate amount of $2,500,000. The Company previously sold approximately $6,234,000 of shares…

Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing. ​ On June 10, 2026, Soligenix, Inc. (the “Company”) received a written notice (the “Bid Price Notice”) from the Listing Qualifications department (the “Nasdaq Staff”) of The Nasdaq Stock Market (“Nasdaq”) indicating that the Company is not in compliance with the $1.00 minimum bid price requirement set forth in Nasdaq Listing Rule 5550(a)(2) for continued listing on the Nasdaq Capital Market. T…

Chief Medical Officer and Senior Vice President — Richard C. Straube, MD: Dr. Richard C. Straube retired from his employment and entered into a consulting agreement.

Other Events. Termination of the HyBryte™ Development Program ​ As previously reported in the Company’s Current Report on Form 8-K filed on April 28, 2026, the Data Monitoring Committee (the “DMC”) completed an interim efficacy analysis of the Company’s confirmatory Phase 3 FLASH2 (Fluorescent Light Activated Synthetic Hypericin 2) clinical trial evaluating HyBryte™ (synthetic hypericin) for the treatment of cutaneous T-cell lymphoma and recommended that the study be halted for futility. Foll…

Other Events. On May 28, 2026, Soligenix, Inc. (the “Company”) filed a prospectus supplement (the “Current Prospectus Supplement”) to increase the maximum aggregate offering amount of the shares of the Company’s common stock, par value $0.001 per share, issuable under the At Market Issuance Sales Agreement dated January 23, 2026 (the “Sales Agreement”) with Rodman & Renshaw LLC, by an additional aggregate amount of $2,956,000. The Company previously sold approximately $3,445,000 of shares of…

Other Events. On January 23, 2026, Soligenix, Inc. (the “Company”) and Rodman & Renshaw, LLC (“Rodman”) entered into an At Market Issuance Sales Agreement (as amended, the “Sales Agreement”), pursuant to which the Company may sell from time to time, at its option, shares of its common stock, par value $0.001 per share, having an aggregate offering price of up to $3,450,000, through Rodman, as sales agent. Under the Sales Agreement, the Company will set the parameters for the sale of shares, i…

Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing. Previously Disclosed Background ​ As previously reported, on August 15, 2025, Soligenix, Inc. (the “Company”) received a written notice from The Nasdaq Stock Market LLC (“Nasdaq”) advising the Company that it was not in compliance with the minimum stockholders’ equity requirement for continued listing on The Nasdaq Capital Market. Nasdaq Listing Rule 5550(b)(1) requires companies listed on The…

Entry into a Material Definitive Agreement On September 25, 2025, Soligenix, Inc., a Delaware corporation (the “Company”) entered into a Securities Purchase Agreement with certain investors (the “Investors”), pursuant to which the Company agreed to issue and sell to the Investors in a public offering (the “Offering”) (i) 4,064,080 shares of the Company’s common stock, (ii) pre-funded warrants to purchase 1,491,480 shares of the Company’s common stock and (iii) common warrants to purchase 5,55…

Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing. ​ On August 15, 2025, Soligenix, Inc. (the “Company”) received notice (the “Notice”) from The Nasdaq Stock Market LLC (“Nasdaq”) advising the Company that it is not in compliance with the minimum stockholders’ equity requirement for continued listing on The Nasdaq Capital Market. Nasdaq Listing Rule 5550(b)(1) requires companies listed on The Nasdaq Capital Market to maintain stockholders’ equ…

The filing is about the approval of a new equity incentive plan and related agreements, not a management change.

Termination of a Material Definitive Agreement. ​ On February 5, 2025, Soligenix, Inc. (the “Company”) and its subsidiaries repaid in full all outstanding obligations due under, and terminated, the Loan and Security Agreement (as previously amended, the “Loan Agreement”) dated December 15, 2020 with Pontifax Medison Finance (Israel) L.P. and Pontifax Medison Finance (Cayman) L.P. (collectively, the “Lenders”) and Pontifax Medison Finance GP, L.P., in its capacity as administrative agent and c…

Creation of a Direct Financial Obligation or an Obligation under an Off-Balance Sheet Arrangement of a Registrant. ​ The information set forth above in

Entry into a Material Definitive Agreement. ​ On October 8, 2024, Soligenix, Inc. (the “Company”) and its subsidiaries, Soligenix UK Limited, Enteron Pharmaceuticals, Inc., Soligenix BioPharma Canada Incorporated, Soligenix NE B.V., and Soligenix Biopharma HI, Inc., as borrowers (collectively referred to as the “Borrower”), entered into an amendment (the “Amendment”) to the Loan and Security Agreement (as previously amended, the “Loan Agreement”) dated December 15, 2020 with Pontifax Medison…

Other Events. ​ On August 16, 2024, Soligenix, Inc. (the “Company”) and A.G.P./Alliance Global Partners (“AGP”) entered into an At Market Issuance Sales Agreement (as amended, the “Sales Agreement”), pursuant to which the Company may sell from time to time, at its option, shares of its common stock, par value $0.001 per share, having an aggregate offering price of up to $5.8 million, through AGP, as sales agent. ​ Under the Sales Agreement, the Company will set the parameters for the sale of…

Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing. Previously Disclosed Background ​ As previously disclosed, on June 23, 2023, Soligenix, Inc. (the “Company”) received a letter from the Listing Qualifications Department of The Nasdaq Stock Market LLC (“Nasdaq”) stating that the Company was not in compliance with Nasdaq Listing Rule 5450(a)(1) (the “Minimum Bid Price Rule”) because the Company’s common stock failed to maintain a minimum closin…

Unregistered Sales of Equity Securities. ​ The disclosure required by this Item and included in

Entry into a Material Definitive Agreement. ​ On July 9, 2024, Soligenix, Inc. (the “Company”) entered into a warrant inducement agreement (the “Inducement Agreement”) with certain holders (the “Holders”) of the Company’s existing Warrant to Purchase Shares of Common Stock (“Existing Warrants”) to purchase shares of common stock, par value $0.001 per share (the “Common Stock”), of the Company. Pursuant to the Inducement Agreement, the Holders agreed to exercise for cash their Existing Warrant…

Material Modification to Rights of Security Holders. ​ To the extent required by

The excerpt is incomplete and does not provide sufficient information to determine the nature of the event.

Entry into a Material Definitive Agreement On April 17, 2024, Soligenix, Inc., a Delaware corporation (the “Company”) entered into a Securities Purchase Agreement with certain investors (the “Investors”), pursuant to which the Company agreed to issue and sell to the Investors in a public offering (the “Offering”) (i) 3,275,000 shares of the Company’s common stock, (ii) pre-funded warrants to purchase 8,600,000 shares of the Company’s common stock and (iii) common warrants to purchase 11,875,0…